OX40L blockade is therapeutic in arthritis, despite promoting osteoclastogenesis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 6, 2014, Pages 2289-2294

  Findlay, Emily Gwyer ^a,e   Danks, Lynett ^b   Madden, Jodie ^a   Cavanagh, Mary M ^a   McNamee, Kay ^b   McCann, Fiona ^b   Snelgrove, Robert J ^a   Shaw, Stevan ^c   Feldmann, Marc ^d   Taylor, Peter Charles ^d   Horwood, Nicole J ^d   Hussell, Tracy ^a,f  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UCB PHARMA   (Belgium)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; CYTOKINES; HOMEOSTASIS; INFLAMMATION MEDIATORS; MEMBRANE GLYCOPROTEINS; MICE; OSTEOCLASTS; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTORS;

EID: 84893836044     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1321071111     Document Type: Article

References (45)

1. Feldmann M, Maini RN (2003) Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med 9(10):1245-1250.
2. Caporali R, Caprioli M, Bobbio-Pallavicini F, Montecucco C (2008) DMARDS and infections in rheumatoid arthritis. Autoimmun Rev 8(2):139-143.
3. Berner B, Wolf G, Hummel KM, Müller GA, Reuss-Borst MA (2000) Increased expression of CD40 ligand (CD154) on CD4+ T cells as a marker of disease activity in rheumatoid arthritis. Ann Rheum Dis 59(3):190-195.
4. Tellander AC, Michaëlsson E, Brunmark C, Andersson M (2000) Potent adjuvant effect by anti-CD40 in collagen-induced arthritis. Enhanced disease is accompanied by increased production of collagen type-II reactive IgG2a and IFN-gamma. J Autoimmun 14(4):295-302.
5. Li L, Wang H, Wang B (2008) Anergic cells generated by blocking CD28 and CD40 costimulatory pathways in vitro ameliorate collagen induced arthritis. Cell Immunol 254(1):39-45.
6. Boumpas DT, et al.; BG9588 Lupus Nephritis Trial Group (2003) A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 48(3):719-727.
7. Croft M (2010) Control of immunity by the TNFR-related molecule OX40 (CD134). Annu Rev Immunol 28:57-78.
8. Morimoto S, et al. (2000) CD134L engagement enhances human B cell Ig production: CD154/CD40, CD70/CD27, and CD134/CD134L interactions coordinately regulate T celldependent B cell responses. J Immunol 164(8):4097-4104.
9. Passacantando A, et al. (2006) Synovial fluid OX40T lymphocytes of patients with rheumatoid arthritis display a Th2/Th0 polarization. Int J Immunopathol Pharmacol 19(3):499-505.
10. Wong BR, et al. (1997) TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 272(40): 25190-25194.
11. Anderson DM, et al. (1997) A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390(6656):175-179.
12. Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423(6937):337-342.
13. Yasuda H, et al. (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95(7):3597-3602.
14. Loser K, et al. (2006) Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nat Med 12(12):1372-1379.
15. Choi Y, et al. (2001) Osteoclastogenesis is enhanced by activated B cells but suppressed by activated CD8(+) T cells. Eur J Immunol 31(7):2179-2188.
16. Croucher PI, et al. (2001) Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 98(13):3534-3540.
17. Leibbrandt A, Penninger JM (2008) RANK/RANKL: Regulators of immune responses and bone physiology. Ann N Y Acad Sci 1143:123-150.
18. Kong YY, et al. (1999) Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402(6759):304-309.
19. Hofbauer LC, et al. (2000) The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 15(1):2-12.
20. Seeuws S, et al. (2010) A multiparameter approach to monitor disease activity in collagen-induced arthritis. Arthritis Res Ther 12(4):R160.
21. Evans KE, Fox SW (2007) Interleukin-10 inhibits osteoclastogenesis by reducing NFATc1 expression and preventing its translocation to the nucleus. BMC Cell Biol 8:4.
22. Mohamed SG, et al. (2007) Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells. Bone 41(4):592-602.
23. Toraldo G, Roggia C, Qian WP, Pacifici R, Weitzmann MN (2003) IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells. Proc Natl Acad Sci USA 100(1):125-130.
24. Horwood NJ, et al. (1999) Activated T lymphocytes support osteoclast formation in vitro. Biochem Biophys Res Commun 265(1):144-150.
25. Takayanagi H, et al. (2000) T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 408(6812):600-605.
26. Lomaga MA, et al. (1999) TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev 13(8):1015-1024.
27. Naito A, et al. (1999) Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells 4(6):353-362.
28. Wang Q, et al. (2004) Characterization and functional study of five novel monoclonal antibodies against human OX40L highlight reverse signalling: Enhancement of IgG production of B cells and promotion of maturation of DCs. Tissue Antigens 64(5): 566-574.
29. Hussell T, Snelgrove R, Humphreys IR, Williams AE (2004) Co-stimulation: Novel methods for preventing viral-induced lung inflammation. Trends Mol Med 10(8): 379-386.
30. Grcevic D, Lee SK, Marusic A, Lorenzo JA (2000) Depletion of CD4 and CD8 T lymphocytes in mice in vivo enhances 1,25-dihydroxyvitamin D3-stimulated osteoclastlike cell formation in vitro by a mechanism that is dependent on prostaglandin synthesis. J Immunol 165(8):4231-4238.
31. John V, Hock JM, Short LL, Glasebrook AL, Galvin RJ (1996) A role for CD8+ T lymphocytes in osteoclast differentiation in vitro. Endocrinology 137(6):2457-2463.
32. Duttagupta PA, Boesteanu AC, Katsikis PD (2009) Costimulation signals for memory CD8+ T cells during viral infections. Crit Rev Immunol 29(6):469-486.
33. Salek-Ardakani S, Moutaftsi M, Sette A, Croft M (2011) Targeting OX40 promotes lung-resident memory CD8 T cell populations that protect against respiratory poxvirus infection. J Virol 85(17):9051-9059.
34. Humphreys IR, et al. (2003) A critical role for OX40 in T cell-mediated immunopathology during lung viral infection. J Exp Med 198(8):1237-1242.
35. Rosenblum H, Amital H (2011) Anti-TNF therapy: Safety aspects of taking the risk. Autoimmun Rev 10(9):563-568.
36. Ivashkiv LB, Zhao B, Park-Min KH, Takami M (2011) Feedback inhibition of osteoclastogenesis during inflammation by IL-10, M-CSF receptor shedding, and induction of IRF8. Ann N Y Acad Sci 1237:88-94.
37. Cella M, et al. (2003) Impaired differentiation of osteoclasts in TREM-2-deficient individuals. J Exp Med 198(4):645-651.
38. Boot EP, et al. (2005) CD134 as target for specific drug delivery to auto-aggressive CD4+ T cells in adjuvant arthritis. Arthritis Res Ther 7(3):R604-R615.
39. Sabbagh L, Snell LM, Watts TH (2007) TNF family ligands define niches for T cell memory. Trends Immunol 28(8):333-339.
40. Croft M (2009) The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol 9:271-285.
41. Fousteri G, et al. (2011) Nasal cardiac myosin peptide treatment and OX40 blockade protect mice from acute and chronic virally-induced myocarditis. J Autoimmun 36(3-4):210-220.
42. Karulf M, Kelly A, Weinberg AD, Gold JA (2010) OX40 ligand regulates inflammation and mortality in the innate immune response to sepsis. J Immunol 185(8):4856-4862.
43. Murata K, et al. (2000) Impairment of antigen-presenting cell function in mice lacking expression of OX40 ligand. J Exp Med 191(2):365-374.
44. Danks L, Workman S, Webster D, Horwood NJ (2011) Elevated cytokine production restores bone resorption by human Btk-deficient osteoclasts. J Bone Miner Res 26(1): 182-192.
45. Notley CA, McCann FE, Inglis JJ, Williams RO (2010) ANTI-CD3 therapy expands the numbers of CD4+ and CD8+ Treg cells and induces sustained amelioration of collagen-induced arthritis. Arthritis Rheum 62(1):171-178.